Mustang Bio Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
80
- Stock Symbol
-
MBIO
- Share Price
-
$0.22
- (As of Wednesday Closing)
Mustang Bio General Information
Description
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Contact Information
Website
www.mustangbio.comCorporate Office
- 377 Plantation Street
- Worcester, MA 01605
- United States
Corporate Office
- 377 Plantation Street
- Worcester, MA 01605
- United States
Mustang Bio Timeline
Mustang Bio Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.22 | $0.23 | $0.13 - $2.11 | $8.2M | 37.2M | 1.49M | -$2.72 |
Mustang Bio Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 15,848 | 5,456 | (17,711) | 36,303 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (33,736) | (48,913) | (71,824) | (64,417) |
| Net Income | (32,064) | (51,602) | (77,525) | (66,370) |
| Total Assets | 8,519 | 17,742 | 92,422 | 125,170 |
| Total Debt | 1,085 | 2,498 | 31,382 | 2,033 |
Mustang Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Mustang Bio Comparisons
Industry
Financing
Details
Mustang Bio Competitors (91)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Caribou Biosciences | Formerly VC-backed | Berkeley, CA | ||||
| Bluebird Bio | Formerly VC-backed | Somerville, MA | ||||
| Vor Biopharma | Formerly VC-backed | Cambridge, MA | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Poseida Therapeutics | Formerly VC-backed | San Diego, CA |
Mustang Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Mustang Bio Patents
Mustang Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220072043-A1 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Pending | 10-Sep-2020 | ||
| AU-2021342126-A1 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Pending | 10-Sep-2020 | ||
| EP-4210831-A2 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Pending | 10-Sep-2020 | ||
| AU-2021342126-A9 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Pending | 10-Sep-2020 | ||
| CA-3194747-A1 | Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer | Pending | 10-Sep-2020 | A61K35/17 |
Mustang Bio Executive Team (9)
| Name | Title | Board Seat |
|---|---|---|
| Manuel Litchman MD | President, Chief Executive Officer & Board Member | |
| James Murphy | Ad interim Chief Financial Officer | |
| James Edinger Ph.D | Chief Scientific Officer | |
| Bruce Dezube | Chief Medical Officer | |
| Greg Furrow | Chief Quality Officer |
Mustang Bio Board Members (6)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member | ||
| Self | Board Member | ||
| Mustang Bio | President, Chief Executive Officer & Board Member | ||
| Self | Chairman & Board Member | ||
| Mustang Bio | Chairman of the Board of Directors |
Mustang Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Mustang Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Mustang Bio ESG
Risk Overview
Risk Rating
Updated June, 22, 2022
38.29 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,638
Rank
Percentile
Pharmaceuticals
Industry
of 1,008
Rank
Percentile
Pharmaceuticals
Subindustry
of 473
Rank
Percentile
Mustang Bio FAQs
-
When was Mustang Bio founded?
Mustang Bio was founded in 2015.
-
Who is the CEO of Mustang Bio?
Manuel Litchman MD is the CEO of Mustang Bio.
-
Where is Mustang Bio headquartered?
Mustang Bio is headquartered in Worcester, MA.
-
What is the size of Mustang Bio?
Mustang Bio has 80 total employees.
-
What industry is Mustang Bio in?
Mustang Bio’s primary industry is Biotechnology.
-
Is Mustang Bio a private or public company?
Mustang Bio is a Public company.
-
What is Mustang Bio’s stock symbol?
The ticker symbol for Mustang Bio is MBIO.
-
What is the current stock price of Mustang Bio?
As of 02-Oct-2024 the stock price of Mustang Bio is $0.22.
-
What is the current market cap of Mustang Bio?
The current market capitalization of Mustang Bio is $8.2M.
-
Who are Mustang Bio’s competitors?
Caribou Biosciences, Bluebird Bio, Vor Biopharma, Allogene Therapeutics, and Poseida Therapeutics are some of the 91 competitors of Mustang Bio.
-
What is Mustang Bio’s annual earnings per share (EPS)?
Mustang Bio’s EPS for 12 months was -$2.72.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
